Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

被引:5
|
作者
Lawson, Alexander [1 ]
Kamarajah, Sivesh K. [2 ]
Parente, Alessandro [2 ]
Pufal, Kamil [1 ]
Sundareyan, Ramanivas [3 ]
Pawlik, Timothy M. [4 ]
Ma, Yuk Ting [5 ]
Shah, Tahir [6 ]
Kharkhanis, Salil [3 ]
Dasari, Bobby V. M. [2 ,7 ]
机构
[1] Univ Birmingham, Birmingham Med Sch, Birmingham B15 2TT, England
[2] Queen Elizabeth Hosp, Dept HPB & Liver Transplantat, Birmingham B15 2TH, England
[3] Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, England
[4] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[5] Queen Elizabeth Hosp, Dept Oncol, Birmingham B15 2TH, England
[6] Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, England
关键词
hepatocellular carcinoma; transarterial embolisation; transarterial chemoembolisation; TRANSCATHETER ARTERIAL EMBOLIZATION; DRUG-ELUTING BEADS; CONVENTIONAL CHEMOEMBOLIZATION; BLAND EMBOLIZATION; TRIAL;
D O I
10.3390/cancers15123166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review
    Wang, Guiliang
    Liu, Yan
    Zhou, Shu-feng
    Qiu, Ping
    Xu, Linfang
    Wen, Ping
    Wen, Jianbo
    Xiao, Xianzhong
    HEPATOLOGY INTERNATIONAL, 2016, 10 (03) : 501 - 510
  • [22] Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
    Mi, Shizheng
    Nie, Yang
    Xie, Changming
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (09) : 1070 - 1079
  • [23] Radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma: A systematic review and meta-analysis
    Ming-Zheng Hu
    Shao-Fang Li
    World Journal of Meta-Analysis, 2015, (06) : 295 - 303
  • [24] Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
    Qi-Han Fu
    Qi Zhang
    Xue-Li Bai
    Qi-Da Hu
    Wei Su
    Yi-Wen Chen
    Ri-Ga Su
    Ting-Bo Liang
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1429 - 1440
  • [25] Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
    Fu, Qi-Han
    Zhang, Qi
    Bai, Xue-Li
    Hu, Qi-Da
    Su, Wei
    Chen, Yi-Wen
    Su, Ri-Ga
    Liang, Ting-Bo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (08) : 1429 - 1440
  • [26] Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Yang, Man
    Yuan, Jin-Qiu
    Bai, Ming
    Han, Guo-Hong
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (10) : 6575 - 6582
  • [27] Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis
    Chen, Zhen-Hua
    Zhang, Xiu-Ping
    Zhou, Teng-Fei
    Wang, Kang
    Wang, Hang
    Chai, Zong-Tao
    Shi, Jie
    Guo, Wei-Xing
    Cheng, Shu-Qun
    EJSO, 2019, 45 (11): : 2188 - 2196
  • [28] Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis
    Jin, Piao-Piao
    Shao, Shi-Yi
    Wu, Wang-Teng
    Zhao, Xin-Yu
    Huang, Bing-Feng
    Fu, Qi-Han
    Que, Ri-Sheng
    Hu, Qi-Da
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (12) : 1058 - 1069
  • [29] TRANSARTERIAL CHEMOEMBOLIZATION VERSUS TRANSARTERIAL RADIOEMBOLIZATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA: A META-ANALYSIS
    Brown, Andrew
    Kassab, Ihab A.
    Chen, Vincent L.
    Townsend, Whitney A.
    Singal, Amit G.
    Parikh, Neehar D.
    HEPATOLOGY, 2019, 70 : 234A - 235A
  • [30] Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Yang, Yi
    Si, Tongguo
    CANCER BIOLOGY & MEDICINE, 2018, 15 (03) : 299 - 310